<DOC>
	<DOCNO>NCT00772525</DOCNO>
	<brief_summary>The primary objective study evaluate effect Nerispirdine ( 50 mg 400 mg ) placebo give orally single dose week crossover design latency Visual Evoked Potentials ( VEP ) P100 optic nerve . Secondary objective include evaluation effect Nerispirdine VEP amplitude visual parameter include visual acuity contrast , well evaluation safety tolerability Nerispirdine patient Multiple Sclerosis ( MS ) . Contrast sensitivity visual acuity examination ( addition Optical Coherence Tomography [ OCT ] VEPs ) need screening period define etiologic relationship ( non-MS relate impairment ) assess effect treatment age-related eye disease versus MS-related vision impairment .</brief_summary>
	<brief_title>Single Oral Doses Study Nerispirdine Visual Function Patients With Multiple Sclerosis</brief_title>
	<detailed_description>The crossover design include 3 treatment period 1 week apart 6 treatment sequence . Study participation 5 week .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<criteria>Clinically definite MS ( McDonald criterion ) , include patient remittingrelapsing , secondary progressive , progressiverelapsing , primary progressive MS past history Optic Neuritis . Multiple sclerosis exacerbation within 60 day Screening Visit relapse involve visual field visual acuity No eye appropriate degree lesion study define criterion base degree visual acuity deficit , refractive error , VEP P100 latency average retinal nerve fiber layer thickness measure Optical Coherence Tomography ( OCT ) Any MSunrelated prior ophthalmological impairment ( eg , compressive , ischemic , toxic , nutritional optic neuropathy , Leber 's hereditary optic atrophy ) Previously expose 3,4diaminopyridine 4aminopyridine The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Visual acuity</keyword>
	<keyword>Contrast sensitivity</keyword>
	<keyword>Visual Evoked Potentials</keyword>
	<keyword>Optical Coherence Tomography</keyword>
</DOC>